Anne Altmeyer
Corbus Pharmaceuticals HoldingsAbout Anne Altmeyer
Anne Altmeyer, Ph.D., age 60, has served as an independent director of Corbus Pharmaceuticals Holdings, Inc. since September 20, 2022; she is President, CEO, and a director of TigaTx, Inc. (since June 2021), and joined the board of Antennova Limited as an independent director in July 2024 . She holds a Ph.D. in molecular immunology (Strasbourg University), completed a postdoctoral fellowship at NYU School of Medicine, was a research associate at Cornell University Medical College, and earned an MBA (Rutgers) and MPH (UMDNJ) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Novartis Pharmaceuticals | Business Development and Project Leadership; oversaw Companion Diagnostics BD and alliances | 2004–2015 | Strategic BD and alliance management |
| Baxalta (acquired by Shire) | Vice President, Business Development & Licensing | — | Global transactions for Baxalta businesses |
| Adicet Bio (Nasdaq: ACET) | Chief Business Officer | — | Allogeneic gamma delta T‑cell platform BD |
| Sigilon Therapeutics (acquired by Eli Lilly) | Chief Business Officer | — | Shielded Living Therapeutics BD |
| Merck & Co. | Project Manager | — | Supported multiple therapeutic areas |
External Roles
| Organization | Role | Tenure | Notable Impact |
|---|---|---|---|
| TigaTx, Inc. | President, CEO, Director | Since Jun 2021 | Secured $35.5M non‑dilutive ARPA‑H/NIH funding in 2024 |
| Antennova Limited | Independent Director | Since Jul 2024 | Not disclosed |
Board Governance
- Independence: Board determined Dr. Altmeyer is independent under Nasdaq rules; all standing committees comprise independent directors .
- Committees: Member, Compensation Committee; not a chair. Not a member of Audit or Nominating & Corporate Governance .
- Attendance: The Board met five times in 2024; each director attended at least 75% of aggregate board and applicable committee meetings in 2024 .
- Compensation Committee practices: Nine meetings in 2024; uses independent consultant OneDigital Human Resources Consulting directly engaged by the committee and not hired by management .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash (2024) | $47,500 | Matches $40,000 annual director retainer plus $7,500 Compensation Committee member fee |
| Annual Director Retainer (policy) | $40,000 | Standard for non‑employee directors |
| Committee Membership Fees (policy) | Compensation: $7,500; Audit: $10,000; Nominating & Governance: $5,000 | Applies to non‑chair members |
| Committee Chair Fees (policy) | Audit: $20,000; Compensation: $15,000; Nominating & Governance: $10,000 | Not applicable to Altmeyer (not a chair) |
Performance Compensation
| Equity Component | 2024 Grant Date Fair Value | Holdings/Counts | Vesting/Terms |
|---|---|---|---|
| Stock Awards (RSUs), 2024 | $115,495 | 2,783 RSUs held as of 12/31/2024 | Annual Non‑Employee Director Grant; vesting as determined annually by the Compensation Committee |
| Option Awards, 2024 | $113,329 | Options to purchase 13,390 shares held as of 12/31/2024 | Upon change in control, 100% of shares underlying director options vest and become exercisable immediately prior to such change |
| Performance Metrics | — | — | No director performance metrics disclosed; director equity grants are time‑based per policy |
Other Directorships & Interlocks
- Current public company directorships: None disclosed beyond CRBP; external board role at Antennova Limited (status not disclosed as public) .
- Prior public company boards: None disclosed; prior roles were operating/executive positions at public biopharmas (Adicet Bio; Sigilon) rather than directorships .
- Interlocks/conflicts: None disclosed in proxy; Audit Committee reviews and approves related‑party transactions .
Expertise & Qualifications
- Scientific and translational expertise in immunology and oncology BD; advanced degrees (Ph.D., MBA, MPH); leadership across Novartis, Baxalta, Adicet, and Sigilon .
- Selected for board due to business leadership and deep biopharma experience .
Equity Ownership
| Metric (as of Mar 21, 2025 unless noted) | Value | Source |
|---|---|---|
| Total beneficial ownership (shares) | 13,390 (includes options exercisable within 60 days) | Proxy beneficial ownership table and footnote |
| Ownership % of outstanding | <1% (*) | Based on 12,232,228 shares outstanding |
| Composition: Presently exercisable options | 13,390 | Footnote confirming “Presently Exercisable Options” |
| RSUs held (12/31/2024) | 2,783 units | Director holdings detail |
Recent insider transactions and updated holdings:
| Item | Date | Detail | Source |
|---|---|---|---|
| Option exercise | Oct 20, 2025 | Exercised 1,060 options at $4.80 (code M) | |
| Sale of common shares | Oct 20, 2025 | Sold 1,060 shares at $20.50 (code S) under Rule 10b5‑1 plan adopted Nov 14, 2024 | |
| Shares beneficially owned after transactions | Oct 20–21, 2025 | 6,191 common shares direct | |
| Unvested RSUs | Granted May 30, 2025 | 4,800 RSUs vest 100% one‑year from grant | |
| Remaining options | After exercise | 4,247 options fully vested at $4.80, expire Sep 26, 2032 |
Governance Assessment
- Board effectiveness: Altmeyer serves on the Compensation Committee (9 meetings in 2024) alongside independent directors; committee uses an independent consultant not engaged by management—positive governance signal .
- Independence and engagement: Board determined independence; attendance met at least 75% threshold in 2024; board held five meetings—no attendance red flags disclosed .
- Director compensation mix: Balanced cash retainer plus time‑based RSUs and options; 2024 cash fees were $47,500; equity grants had fair values of $115,495 (RSUs) and $113,329 (options), aligning incentives with shareholders via equity, though no director‑specific performance metrics disclosed .
- Ownership alignment: Proxy shows <1% ownership; holdings dominated by options/RSUs; recent 10b5‑1 plan sale in Oct 2025 appears routine; no pledging disclosed—alignment adequate for small‑cap biotech but low absolute ownership may be viewed as a modest alignment gap .
- Conflicts/related‑party transactions: Company reports none above thresholds since Jan 1, 2023; Audit Committee oversees and pre‑approves related‑party transactions—no conflict red flags identified for Altmeyer .
- Risk indicators: Anti‑hedging policy prohibits collars/forward sale contracts; delinquent Section 16(a) reports—none noted for 2024; indemnification and D&O insurance in place .
RED FLAGS: None disclosed for related‑party transactions, hedging/pledging, or attendance. Low absolute share ownership (<1%) is a mild alignment risk typical for non‑employee directors at development‑stage biotechs .